



## Unleashing the potential of Real-World Evidence in the area of rare diseases

Providing Better Understanding and Fostering Access to Therapies

1 March 2021 // 14:00 to 16:00 CET

Virtual event, access link will be provided ahead of the date

As part of its efforts to support patients with Myasthenia Gravis (MG), in 2020 global immunology company argenx launched MyRealWorldMG, a global observational study aimed at collecting “Real-World Evidence” on the impact of Myasthenia Gravis on patients’ daily lives. The study is being conducted in collaboration with MG Patient Organisations and clinicians from 9 countries – Germany, Spain, Italy, Belgium, France, the UK, the US, Canada and Japan.

On the basis of the experience gathered through MyRealWorldMG, and on the occasion of Rare Disease Day, we have the pleasure to invite you to our **virtual event** entitled **“Unleashing the Potential of Real-World Evidence in the Area of Rare Diseases: Providing Better Understanding and Fostering Access to Therapies”**. The event is hosted by the Italian patient organization Associazione Italiana Miastenia (AIM) and sponsored by argenx.

An expert high-level panel will exchange views and best practices on the benefits and potential that Real-World Evidence studies can bring in the area of rare diseases, as well as the obstacles that the implementation of such studies continues to face in practice.

### Programme\*

#### Welcoming speech by host

*Renato Mantegazza, President of AIM*

#### The Scientific Perspective: Presentation of MyRealWorld MG observational study

*Mark Larkin, Founder and CEO, Vitaccess*

#### The Patients' Perspective

*Marguerite Friconneau, Expert Patient, Patient Advocate  
in the Scientific Board of the MyRealWorld MG Study*

#### The Economic Perspective

*Lieven Annemans, Senior Professor, Economics of Health and Wellbeing,  
Ghent University and Brussels University (VUB); Advisor and lecturer  
about health technology assessment (HTA)*

#### The Regulators' Perspective

*Brieuc Van Damme, Director-General Healthcare, RIZIV-INAMI*

#### The European Perspective

*Participant to be confirmed*

#### Q&A discussion with panellists

*Opened by Sarah Emond, Executive Vice President and  
Chief Operating Officer, Institute for Clinical and Economic Review (ICER)*

#### Closing Remarks

*Anant Murthy, General Manager, Europe, argenx*

**Moderated by: Anant Murthy, General Manager, Europe, argenx**

*\*The programme may vary slightly in view of the speakers' input*

[Register here](#)